The present invention relate to a novel crystalline form of rosuvastatin calcium hereinafter designated as Form E as well as processes for its manufacture and pharmaceutical composition comprising rosuvastatin crystalline Form E, which is useful as an agent for treating hyperlipidemia, hypercholesterolemia and atherosclerosis.